NASDAQ:HALO - Halozyme Therapeutics Stock Price, Forecast & News

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.05. The biopharmaceutical company had revenue of $46.20 million for the quarter, compared to analysts' expectations of $54.96 million. Halozyme Therapeutics had a negative return on equity of 15.76% and a negative net margin of 19.73%. The business's quarterly revenue was up 80.5% on a year-over-year basis. During the same period last year, the company posted ($0.19) earnings per share. View Halozyme Therapeutics' Earnings History.

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Halozyme Therapeutics.

Halozyme Therapeutics will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Halozyme Therapeutics updated its FY20 earnings guidance on Tuesday, January, 14th. The company provided earnings per share (EPS) guidance of $0.60-0.70 for the period, compared to the Thomson Reuters consensus estimate of $0.56. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $224.10 million.

6 analysts have issued 1-year target prices for Halozyme Therapeutics' stock. Their forecasts range from $16.00 to $35.00. On average, they expect Halozyme Therapeutics' stock price to reach $24.50 in the next year. This suggests a possible upside of 16.0% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Halozyme Therapeutics.

News articles about HALO stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Halozyme Therapeutics earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Halozyme Therapeutics.

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Gilead Sciences (GILD) and Aegean Marine Petroleum Network (ANW).

Halozyme Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Third Security LLC (4.81%), William Blair Investment Management LLC (4.32%), Artisan Partners Limited Partnership (3.59%), State Street Corp (3.06%), Pictet Asset Management Ltd. (1.96%) and FMR LLC (1.60%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros and Randal J Kirk. View Institutional Ownership Trends for Halozyme Therapeutics.

HALO stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Third Security LLC, Goldman Sachs Group Inc., Sofinnova Investments Inc., Jacobs Levy Equity Management Inc., Man Group plc, FMR LLC and New York State Common Retirement Fund. View Insider Buying and Selling for Halozyme Therapeutics.

HALO stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Renaissance Technologies LLC, William Blair Investment Management LLC, Partner Fund Management L.P., Granite Investment Partners LLC, Prudential Financial Inc., Kornitzer Capital Management Inc. KS and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Halozyme Therapeutics.

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HALO stock can currently be purchased for approximately $21.12.

Halozyme Therapeutics has a market capitalization of $3.09 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics.

The official website for Halozyme Therapeutics is http://www.halozyme.com/.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]